This report was first published by Endpoints News. To see the original version, click here
Corvus Pharmaceuticals’ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts’ best-case scenario.
The company’s share price $CRVS soared more than 160% in Tuesday trading.
您已阅读11%（356字），剩余89%（2936字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。